144 related articles for article (PubMed ID: 25394023)
1. A clinically useful risk-score for chronic kidney disease in HIV infection.
Mocroft A; Lundgren J; Ross M; Law M; Reiss P; Kirk O; Smith C; Wentworth D; Heuhaus J; Fux C; Moranne O; Morlat P; Johnson M; Ryom L;
J Int AIDS Soc; 2014; 17(4 Suppl 3):19514. PubMed ID: 25394023
[TBL] [Abstract][Full Text] [Related]
2. Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study.
Mocroft A; Lundgren JD; Ross M; Law M; Reiss P; Kirk O; Smith C; Wentworth D; Neuhaus J; Fux CA; Moranne O; Morlat P; Johnson MA; Ryom L; ; ; ; ;
PLoS Med; 2015 Mar; 12(3):e1001809. PubMed ID: 25826420
[TBL] [Abstract][Full Text] [Related]
3. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study.
Mocroft A; Lundgren JD; Ross M; Fux CA; Reiss P; Moranne O; Morlat P; Monforte Ad; Kirk O; Ryom L;
Lancet HIV; 2016 Jan; 3(1):e23-32. PubMed ID: 26762990
[TBL] [Abstract][Full Text] [Related]
4. Predictors of advanced chronic kidney disease and end-stage renal disease in HIV-positive persons.
Ryom L; Mocroft A; Kirk O; Ross M; Reiss P; Fux CA; Morlat P; Moranne O; Smith C; El-Sadr W; Law M; Lundgren JD
AIDS; 2014 Jan; 28(2):187-99. PubMed ID: 24361680
[TBL] [Abstract][Full Text] [Related]
5. Estimated Glomerular Filtration Rate Trajectories in HIV-Infected Subjects Treated With Different Ritonavir-Boosted Protease Inhibitors and Tenofovir Disoproxil Fumarate or Abacavir.
Gianotti N; Galli L; Poli A; Salpietro S; Nozza S; Carbone A; Merli M; Ripa M; Lazzarin A; Castagna A
Medicine (Baltimore); 2016 May; 95(22):e3780. PubMed ID: 27258510
[TBL] [Abstract][Full Text] [Related]
6. Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study.
Ryom L; Mocroft A; Kirk O; Worm SW; Kamara DA; Reiss P; Ross M; Fux CA; Morlat P; Moranne O; Smith C; Lundgren JD;
J Infect Dis; 2013 May; 207(9):1359-69. PubMed ID: 23382571
[TBL] [Abstract][Full Text] [Related]
7. Validation of the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) chronic kidney disease risk score in HIV-infected patients in the USA.
Mills AM; Schulman KL; Fusco JS; Brunet L; Hsu R; Beyer A; Prajapati G; Mounzer K; Fusco GP
HIV Med; 2020 May; 21(5):299-308. PubMed ID: 31985887
[TBL] [Abstract][Full Text] [Related]
8. Contribution of Genetic Background and Data Collection on Adverse Events of Anti-human Immunodeficiency Virus (HIV) Drugs (D:A:D) Clinical Risk Score to Chronic Kidney Disease in Swiss HIV-infected Persons With Normal Baseline Estimated Glomerular Filtration Rate.
Dietrich LG; Barceló C; Thorball CW; Ryom L; Burkhalter F; Hasse B; Furrer H; Weisser M; Steffen A; Bernasconi E; Cavassini M; de Seigneux S; Csajka C; Fellay J; Ledergerber B; Tarr PE
Clin Infect Dis; 2020 Feb; 70(5):890-897. PubMed ID: 30953057
[TBL] [Abstract][Full Text] [Related]
9. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients.
Mocroft A; Kirk O; Reiss P; De Wit S; Sedlacek D; Beniowski M; Gatell J; Phillips AN; Ledergerber B; Lundgren JD;
AIDS; 2010 Jul; 24(11):1667-78. PubMed ID: 20523203
[TBL] [Abstract][Full Text] [Related]
10. Does first-line antiretroviral regimen impact risk for chronic kidney disease whatever the risk group?
Flandre P; Pugliese P; Allavena C; Isnard Bagnis C; Cuzin L;
AIDS; 2016 Jun; 30(9):1433-8. PubMed ID: 26891036
[TBL] [Abstract][Full Text] [Related]
11. Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir.
Young J; Schäfer J; Fux CA; Furrer H; Bernasconi E; Vernazza P; Calmy A; Cavassini M; Weber R; Battegay M; Bucher HC;
AIDS; 2012 Mar; 26(5):567-75. PubMed ID: 22398568
[TBL] [Abstract][Full Text] [Related]
12. Birth Outcomes for Pregnant Women with HIV Using Tenofovir-Emtricitabine.
Rough K; Seage GR; Williams PL; Hernandez-Diaz S; Huo Y; Chadwick EG; Currier JS; Hoffman RM; Barr E; Shapiro DE; Patel K;
N Engl J Med; 2018 Apr; 378(17):1593-1603. PubMed ID: 29694825
[TBL] [Abstract][Full Text] [Related]
13. Role of traditional risk factors and antiretroviral drugs in the incidence of chronic kidney disease, ANRS CO3 Aquitaine cohort, France, 2004-2012.
Morlat P; Vivot A; Vandenhende MA; Dauchy FA; Asselineau J; Déti E; Gerard Y; Lazaro E; Duffau P; Neau D; Bonnet F; Chêne G;
PLoS One; 2013; 8(6):e66223. PubMed ID: 23776637
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis C co-infection is associated with an increased risk of incident chronic kidney disease in HIV-infected patients initiating combination antiretroviral therapy.
Rossi C; Raboud J; Walmsley S; Cooper C; Antoniou T; Burchell AN; Hull M; Chia J; Hogg RS; Moodie EE; Klein MB;
BMC Infect Dis; 2017 Apr; 17(1):246. PubMed ID: 28376824
[TBL] [Abstract][Full Text] [Related]
15. Advanced chronic kidney disease, end-stage renal disease and renal death among HIV-positive individuals in Europe.
Ryom L; Kirk O; Lundgren JD; Reiss P; Pedersen C; De Wit S; Buzunova S; Gasiorowski J; Gatell JM; Mocroft A;
HIV Med; 2013 Sep; 14(8):503-8. PubMed ID: 23590641
[TBL] [Abstract][Full Text] [Related]
16. A comparison of estimated glomerular filtration rates using Cockcroft-Gault and the Chronic Kidney Disease Epidemiology Collaboration estimating equations in HIV infection.
Mocroft A; Ryom L; Reiss P; Furrer H; D'Arminio Monforte A; Gatell J; de Wit S; Beniowski M; Lundgren JD; Kirk O;
HIV Med; 2014 Mar; 15(3):144-52. PubMed ID: 24118916
[TBL] [Abstract][Full Text] [Related]
17. Risk of Chronic Kidney Disease among Patients Developing Mild Renal Impairment during Tenofovir-Containing Antiretroviral Treatment.
Lapadula G; Bernasconi DP; Casari S; Maggiolo F; Cauda R; Di Pietro M; Ladisa N; Sighinolfi L; Dal Zoppo S; Sabbatini F; Soria A; Pezzoli C; Mondi A; Costarelli S; Valsecchi MG; Torti C; Gori A;
PLoS One; 2016; 11(9):e0162320. PubMed ID: 27632369
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis C virus viremia increases the incidence of chronic kidney disease in HIV-infected patients.
Peters L; Grint D; Lundgren JD; Rockstroh JK; Soriano V; Reiss P; Grzeszczuk A; Sambatakou H; Mocroft A; Kirk O;
AIDS; 2012 Sep; 26(15):1917-26. PubMed ID: 22781222
[TBL] [Abstract][Full Text] [Related]
19. Incidence of renal toxicity in HIV-infected, antiretroviral-naïve patients starting tenofovir/emtricitabine associated with efavirenz, atazanavir/ritonavir, or lopinavir/ritonavir.
Calza L; Trapani F; Salvadori C; Magistrelli E; Manfredi R; Colangeli V; Di Bari MA; Borderi M; Viale P
Scand J Infect Dis; 2013 Feb; 45(2):147-54. PubMed ID: 22991923
[TBL] [Abstract][Full Text] [Related]
20. Predictors of estimated glomerular filtration rate progression, stabilization or improvement after chronic renal impairment in HIV-positive individuals.
Ryom L; Mocroft A; Kirk O; Reiss P; Ross M; Smith C; Moranne O; Morlat P; Fux CA; Sabin C; Phillips A; Law M; Lundgren JD;
AIDS; 2017 Jun; 31(9):1261-1270. PubMed ID: 28492392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
